Sales & Marketing News | pharmaphorum

News

The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

News

Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.

News

Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus.

News

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.